Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General cellular components via ROS-mediated damage refers to the non-specific oxidative degradation of cellular macromolecules—including DNA, proteins, and lipids—by reactive oxygen species (ROS) such as superoxide and hydroxyl radicals (PMID: 28129551). This mechanism is a central feature of oxidative stress, where an imbalance between ROS production and antioxidant defenses leads to cellular dysfunction and death (NIH, StatPearls). In oncology, several therapeutic modalities, including ionizing radiation and certain chemotherapeutics like doxorubicin, exploit this process to induce apoptosis in cancer cells by overwhelming their redox capacity (PMID: 24751377). Because ROS react indiscriminately with various cellular structures, this mechanism is associated with significant off-target toxicity, such as cardiotoxicity and nephrotoxicity, in healthy tissues (PMID: 16430879). Chronic ROS-mediated damage to cellular components is also a primary driver in the progression of neurodegenerative diseases like Alzheimer's and Parkinson's, as well as the general aging process (PMID: 23626520). Therapeutic interventions often aim to either harness this damage to kill pathogens or cancer cells, or mitigate it using antioxidants to protect vital organs. The lack of specificity makes it a challenging "target" to modulate without affecting normal physiological signaling pathways that also rely on low levels of ROS.
Induction of oxidative stress through the generation of reactive oxygen species (ROS) which non-specifically oxidize lipids (lipid peroxidation), proteins (carbonylation), and DNA (strand breaks), leading to cellular dysfunction and apoptosis (PMID: 28129551, PMID: 24751377).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General cellular components via reactive oxygen species (ROS)-mediated damage (ROS-mediated damage).